AlloVir ALVR Stock
AlloVir Price Chart
AlloVir ALVR Financial and Trading Overview
| AlloVir stock price | 10.02 USD |
| Previous Close | 5.34 USD |
| Open | 5.28 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 5.2 - 5.67 USD |
| 52 Week Range | 3.23 - 10.29 USD |
| Volume | 322.9K USD |
| Avg. Volume | 244.97K USD |
| Market Cap | 521.29M USD |
| Beta (5Y Monthly) | 0.703579 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.76 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.67 USD |
ALVR Valuation Measures
| Enterprise Value | 311.38M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.8274112 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.5834882 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.822 |
Trading Information
AlloVir Stock Price History
| Beta (5Y Monthly) | 0.703579 |
| 52-Week Change | 47.35% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.29 USD |
| 52 Week Low | 3.23 USD |
| 50-Day Moving Average | 4.2 USD |
| 200-Day Moving Average | 6.03 USD |
ALVR Share Statistics
| Avg. Volume (3 month) | 244.97K USD |
| Avg. Daily Volume (10-Days) | 356.38K USD |
| Shares Outstanding | 93.59M |
| Float | 31.51M |
| Short Ratio | 42.18 |
| % Held by Insiders | 50.66% |
| % Held by Institutions | 40.60% |
| Shares Short | 7.29M |
| Short % of Float | 16.67% |
| Short % of Shares Outstanding | 7.79% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -45.049% |
| Return on Equity (ttm) | -86.20% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -170896992 USD |
| Net Income Avi to Common (ttm) | -166030000 USD |
| Diluted EPS (ttm) | -1.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 202.57M USD |
| Total Cash Per Share (mrq) | 2.25 USD |
| Total Debt (mrq) | 33.82M USD |
| Total Debt/Equity (mrq) | 17.48 USD |
| Current Ratio (mrq) | 8.505 |
| Book Value Per Share (mrq) | 2.156 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -127694000 USD |
| Levered Free Cash Flow (ttm) | -70038000 USD |
Profile of AlloVir
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 1100 Winter Street |
| ZIP | 02451 |
| Phone | 617 433 2605 |
| Website | https://www.allovir.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 111 |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Q&A For AlloVir Stock
What is a current ALVR stock price?
AlloVir ALVR stock price today per share is 10.02 USD.
How to purchase AlloVir stock?
You can buy ALVR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AlloVir?
The stock symbol or ticker of AlloVir is ALVR.
Which industry does the AlloVir company belong to?
The AlloVir industry is Biotechnology.
How many shares does AlloVir have in circulation?
The max supply of AlloVir shares is 5.17M.
What is AlloVir Price to Earnings Ratio (PE Ratio)?
AlloVir PE Ratio is now.
What was AlloVir earnings per share over the trailing 12 months (TTM)?
AlloVir EPS is -19.76 USD over the trailing 12 months.
Which sector does the AlloVir company belong to?
The AlloVir sector is Healthcare.
AlloVir ALVR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18350.19 USD — |
-2.64
|
7.23B USD — | 18216.63 USD — | 18992.3 USD — | — - | 7.23B USD — |
| NASDAQ HealthCare IXHC | 993.66 USD — |
-1.66
|
— — | 990.15 USD — | 1016.8 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4486.38 USD — |
-0.37
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8980.1 USD — |
-2.61
|
— — | 8914.08 USD — | 9291.63 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4426.74 USD — |
-2.02
|
— — | 4410.76 USD — | 4543.89 USD — | — - | — — |
- {{ link.label }} {{link}}